Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263792 | 1.00 | FFAR1 (0.40) | FFAR1BRD4ALDH2KCNH2SCN3A | |
| SCHEMBL1263798 | 1.00 | FFAR1 (0.40) | FFAR1BRD4ALDH2KCNH2SCN3A | |
| SCHEMBL1716767 | 0.93 | FFAR1 (0.40) | FFAR1BRD4KCNH2SCN3A | |
| SCHEMBL1716766 | 0.93 | FFAR1 (0.40) | FFAR1BRD4KCNH2SCN3A | |
| SCHEMBL1263796 | 0.93 | FFAR1 (0.41) | FFAR1BRD4ALDH2KCNH2SCN3A | |
| SCHEMBL10087898 | 0.90 | GAA (0.38) | HIF1AGAAMAPT | |
| SCHEMBL1716768 | 0.86 | FFAR1 (0.40) | FFAR1BRD4KCNH2SCN3A | |
| SCHEMBL11937301 | 0.85 | FFAR1 (0.40) | FFAR1HIF1AGAAMAPT | |
| SCHEMBL1263389 | 0.85 | FFAR1 (0.40) | FFAR1HIF1AGAAMAPT | |
| SCHEMBL1263382 | 0.85 | FFAR1 (0.40) | FFAR1HIF1AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227456-B2 | Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-07-24 | — | — | US | claimed |
| JP-4733698-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | claimed |
| EP-1784173-A4 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | KOREA RES INST CHEM TECH (KR) | 2009-07-01 | — | — | EP | claimed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | claimed |
| EP-1784173-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | Korea Research Institute of Chemical Technology (KR) | 2007-05-16 | — | — | EP | claimed |
| WO-2005123054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-12-29 | — | — | WO | claimed |
| US-8227456-B2 | Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-07-24 | — | — | US | disclosed |
| EP-1784173-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | KOREA RES INST CHEM TECH (KR) | 2012-01-18 | — | — | EP | disclosed |
| US-7879835-B2 | treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| EP-1784173-A4 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | KOREA RES INST CHEM TECH (KR) | 2009-07-01 | — | — | EP | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
| EP-1784173-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | Korea Research Institute of Chemical Technology (KR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2005123054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | ARSA, BMP2, BMP1 | FFAR1 1405/4885BRD4 2717/4885ALDH2 1710/4885 |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | CYP24A1, SOST, ACP3 | FFAR1 495/4885BRD4 2531/4885ALDH2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.